Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

VVOS vs RNAZ: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RNAZ Captures Overall Composite Edge (40.5 SELL vs 36.4 SELL), While VVOS Leads 3–2 on Growth & Valuation Pillars

RNAZ Overall Winner 6-Pillar Tally: VVOS 3 – 2 RNAZ (1 Tie) Matrix Metrics: VVOS 1 – 7 RNAZ

As of Nov 20, 2026, TransCode Therapeutics, Inc. (RNAZ) captures the overall head-to-head institutional edge over Vivos Therapeutics, Inc. (VVOS) on higher Unified Composite conviction (40.5/100 SELL vs. 36.4/100 SELL) after splitting the core matrix 7–1 (led by Profitability & Quality, Options & Positioning), while VVOS wins 3–2 across the 6-pillar growth and valuation breakdown. VVOS trades at $0.05 (N/M Forward P/E, -107.9% operating margin) versus RNAZ at $1.16 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: RNAZ earns the overall head-to-head edge with a stronger Unified Composite Score (40.5/100 SELL vs. VVOS 36.4/100 SELL) and 1.27β · 87% Vol risk profile, whereas VVOS leads top-line expansion (+34.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although RNAZ compares more favorably head-to-head, both VVOS (36.4/100 SELL) and RNAZ (40.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: VVOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9); meanwhile RNAZ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VVOS vs RNAZ
VVOS NASDAQ
Vivos Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.05
-5.1% 1D
Market Cap $1.9M
TTM Revenue $21M
Forward P/E N/M
Beta / 30D Vol 1.70β · 111% Vol
Unified Composite Score
36.4 / 100 SELL
Tech 25.0 Fund 35.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -29.8%), weak momentum, RSI 19
RSI-14: 18.9 · SMA20: $0.10 · SMA50: $0.13
RNAZ NASDAQ Head-to-Head Winner
TransCode Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$1.16
-10.77% 1D
Market Cap $22.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.27β · 87% Vol
Unified Composite Score
40.5 / 100 SELL
Tech 25.0 Fund 47.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.5%), weak momentum, RSI 29
RSI-14: 28.6 · SMA20: $1.49 · SMA50: $1.62

6-Pillar Scorecard Institutional Category Breakdown (VVOS 3 – 2 RNAZ)

Columns: Metric · VVOS · RNAZ
1. Valuation Multiples VVOS
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.1x N/M
2. Growth & Scale VVOS
Revenue Growth (YoY) +34.9% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $21M N/A
Market Cap $1.9M $22.5M
3. Profitability & Quality RNAZ
Gross Margin 61.9% N/A
Operating Margin -107.9% 0.0%
Net Profit Margin -121.8% 0.0%
Return on Equity (ROE) -8585.3% -866.1%
4. Balance Sheet & Cash Flow VVOS
Cash Generation (TTM) -$21M EBITDA -$21M
Cash Flow Margin -99.3% EBITDA Mgn N/A
Net Cash / Leverage -8585.3% ROE $1.86 Book/Sh · -866.1% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RNAZ
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VVOS (1) vs RNAZ (7)
Institutional Metric VVOS RNAZ Criterion Row Edge
Market Capitalization
Scale
$1.9M $22.5M Larger Scale RNAZ
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+34.9% +0.0% Higher Growth VVOS
Operating Margin (TTM)
Profitability
-107.9% 0.0% Higher Margin RNAZ
Net Profit Margin
Profitability
-121.8% 0.0% Higher Margin RNAZ
Return on Equity (ROE)
Capital Efficiency
-8585.3% -866.1% Higher ROE RNAZ
52-Week Range Position
Momentum
0% ($0–$3) 1% ($1–$13) Stronger Trend RNAZ
Beta / 30D Volatility
Risk Regime
1.70β · 111% Vol 1.27β · 87% Vol Lower Realized Risk RNAZ
Unified Institutional Score
Composite Signal
36.4 / 100 (SELL) 40.5 / 100 (SELL) Higher Composite RNAZ
Trailing 12M Revenue (USD)
Operating Scale
$21M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
61.9% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$21M EBITDA (-8585.3% ROE) -$21M ($1.86 Book/Sh · -866.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RNAZ +26.89 pp
VVOS: -59.25% · RNAZ: -32.36%
3M Horizon RNAZ +23.45 pp
VVOS: -80.49% · RNAZ: -57.04%
6M Horizon RNAZ +9.74 pp
VVOS: -90.77% · RNAZ: -81.03%
1Y Horizon RNAZ +10.61 pp
VVOS: -97.71% · RNAZ: -87.1%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VVOS vs RNAZ. Trailing 12-month operating profitability (VVOS -107.9% vs RNAZ 0.0%) and valuation multiples (VVOS N/M vs RNAZ N/M Forward P/E) are benchmarked directly in Pillar 4 below.

VVOS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$21M
Gross Margin61.9%
Op. Margin-107.9%
ROE / Fwd P/E-8585.3% · N/M
RNAZ ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-866.1% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VVOS BREAKDOWN
113d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VVOS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RNAZ UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RNAZ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VVOS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.9M market capitalization and -107.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
RNAZ Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $22.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VVOS vs RNAZ Key Questions & Quantitative Answers

As of Nov 20, 2026, TransCode Therapeutics, Inc. (RNAZ) captures the overall head-to-head institutional edge over Vivos Therapeutics, Inc. (VVOS) on higher Unified Composite conviction (40.5/100 SELL vs. 36.4/100 SELL) after splitting the core matrix 7–1 (led by Profitability & Quality, Options & Positioning), while VVOS wins 3–2 across the 6-pillar growth and valuation breakdown. VVOS trades at $0.05 (N/M Forward P/E, -107.9% operating margin) versus RNAZ at $1.16 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: RNAZ earns the overall head-to-head edge with a stronger Unified Composite Score (40.5/100 SELL vs. VVOS 36.4/100 SELL) and 1.27β · 87% Vol risk profile, whereas VVOS leads top-line expansion (+34.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although RNAZ compares more favorably head-to-head, both VVOS (36.4/100 SELL) and RNAZ (40.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: VVOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9); meanwhile RNAZ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VVOS leads the Growth & Scale pillar: VVOS posts +34.9% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (61.9% gross margin, -107.9% operating margin), compared with RNAZ at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, VVOS generates $21M in USD-normalized revenue versus N/A for RNAZ. In operating R&D and SG&A reinvestment, VVOS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RNAZ.

VVOS screens cheaper on headline valuation multiples. VVOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-99.3% EBITDA margin), whereas RNAZ trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VVOS (-8585.3% ROE) versus RNAZ (-866.1% ROE) capital efficiency.

In options market volatility and institutional positioning, VVOS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 111% Vol realized risk). By comparison, RNAZ carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.27β · 87% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.